Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Nov 28, 2018

Keywords

ClinConnect Summary

This clinical trial is looking at how inflammation in the brain might be related to chronic pain and fatigue conditions like fibromyalgia, chronic fatigue syndrome, and multiple sclerosis. Researchers will use a special imaging technique called PET scanning with a substance called [F-18]DPA-714, which helps them see areas in the brain where inflammation is happening. The main goal is to find out if people with these painful conditions have more inflammation in their brains compared to healthy individuals.

To participate, you must be between 18 and 65 years old and either healthy or diagnosed with one of the conditions mentioned. However, there are some important exclusions, such as being pregnant, having certain infections, or being enrolled in another clinical trial. If you join the study, you can expect to undergo imaging to help assess the level of neuroinflammation in your brain, which could help researchers understand these conditions better. This trial is currently recruiting participants, and everyone is welcome regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 to 65 years of age
• • 2. Healthy volunteer OR Clinical diagnosis of Multiple Sclerosis (MS) OR Meets 2016 American College of Rheumatology (ACR) case definition criteria for fibromyalgia OR Meets 1994 Fukuda case definition criteria for Chronic Fatigue Syndrome
• Exclusion Criteria:
• • 1. Contraindication to MRI
• • 2. Pregnancy
• • 3. Lactation
• • 4. Individuals who are unable to participate in the imaging portion due to severity of their medical condition
• • 5. Chronic infectious disease (e.g. HIV, HCV)
• • 6. Viral or bacterial illness requiring medical attention and/or antibiotics within 1 month of study participation
• • 7. Diagnosis of cancer, including leukemia
• • 8. Blood or blood clotting disorder
• • 9. Except for individuals with MS, a diagnosis of autoimmune disease is exclusionary
• • 10. Positive urine β-hCG test day of procedure or a serum -hCG test within 48 hours prior to the administration of \[18F\]DPA-714
• • 11. Currently enrolled in a clinical trial utilizing experimental therapies